The state of Massachusetts currently has 3 active clinical trials seeking participants for Hepatitis B research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
National Liver Cancer Screening Trial
Recruiting
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), an... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Recruiting
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level \>1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/10/2025
Locations: Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts
Conditions: Hepatitis B, HIV Infections
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
Recruiting
This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear \[209668: NCT04449029\], B-Together \[209348: NCT04676724\], B-F... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: GSK Investigational Site, Boston, Massachusetts
Conditions: Hepatitis B